Dry powder drug delivery system and methods

US9802012B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9802012-B2
Application numberUS-201313941365-A
CountryUS
Kind codeB2
Filing dateJul 12, 2013
Priority dateJul 12, 2012
Publication dateOct 31, 2017
Grant dateOct 31, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

First claim

Opening claim text (preview).

We claim: 1. A dry powder inhaler comprising: a) a first element comprising a mouthpiece; b) a second element comprising a cartridge including a powder container and a lid; and c) at least two rigid air conduits; wherein one of the at least two rigid air conduits in a dosing configuration includes a deflector or stem protruding from an undersurface of the lid facing an internal volume of the powder container to direct airflow entering the internal volume of the powder container from a direction parallel to the mouthpiece to a substantially downward direction to a direction substantially parallel to the mouthpiece through the dry powder to a direction substantially perpendicular to the mouthpiece to exit the powder container; and wherein in a containment configuration the dry powder is sealed from the at least two air conduits and from the deflector or stem; wherein the powder container comprising a first vertical wall and a second vertical wall parallel and opposed; wherein in the dosing configuration the deflector or stem is disposed between the first vertical wall and the second vertical wall. 2. The dry powder inhaler of claim 1 having a resistance value to airflow ranging from about 0.065 (√kPa)/liter per minute to about 0.200 (√kPa)/liter per minute. 3. The dry powder inhaler of claim 1 , wherein the dry powder is a formulation for oral inhalation and comprises an amount from about 1 mg to about 50 mg of the dry powder. 4. The dry powder inhaler of claim 3 , wherein the dry powder comprises a drug or an active agent. 5. The dry powder inhaler of claim 4 , wherein the active agent is an endocrine hormone, vaccines, small molecules, including anti-asthmatics, vasodilators, vasoconstrictors, muscle relaxants, or neurotransmitter agonist or antagonists. 6. The dry powder inhaler of claim 3 , wherein the dry powder comprises a peptide, a polypeptide, or fragments thereof, a small organic molecule or a nucleic acid molecule. 7. The dry powder inhaler of claim 6 , wherein said peptide is insulin, glucagon, glucagon-like peptide- 1 , parathyroid hormone, deoxyribonuclease, oxytocin, oxyntomodulin, peptide YY, an exendin, or fragments thereof. 8. The dry powder inhaler of claim 6 , wherein the small organic molecule is a vasodialator, a vasoconstrictor, a neurotransmitter agonist or a neurotransmitter antagonist. 9. The dry powder inhaler of claim 8 , wherein the small organic molecule is a triptan or an opiate. 10. The dry powder inhaler of claim 9 , wherein the triptan is sumatriptan or rizatriptan. 11. The dry powder inhaler of claim 1 , wherein the powder container is integrated into a container housing and filled with a dry powder. 12. The dry powder inhaler of claim 1 , wherein the powder container is provided separate from the inhaler and is filled with a dry powder. 13. The dry powder inhaler of claim 1 , wherein the powder is an amorphous powder. 14. A method of delivering a dry powder to a subject comprising administering to said subject an effective amount of an amorphous powder medicament using the dry powder inhaler of claim 1 . 15. The dry powder inhaler of claim 1 , wherein the one of the at least two rigid air conduits does not have a cross-sectional O-shape. 16. The dry powder inhaler of claim 1 , wherein the dry powder comprises a diketopiperazine or a pharmaceutically acceptable salt thereof. 17. The dry powder inhaler of claim 16 , wherein the diketopiperazine is of the formula 2,5-diketo-3,6-bis(N—X-4-aminobutyl)piperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, malonyl, oxalyl and glutaryl. 18. The dry powder inhaler of claim 17 , wherein the diketopiperazine is 3,6-bis-(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine. 19. A dry powder inhaler comprising: a) a first element comprising a mouthpiece; and b) at least two rigid air conduits; wherein one of the at least two rigid air conduits in a dosing configuration includes a deflector or stem protruding from an undersurface of a lid facing an internal volume of a powder container to direct airflow entering the internal volume of the powder container from a direction parallel to the mouthpiece to a substantially downward direction to a direction substantially parallel to the mouthpiece through the dry powder to a direction substantially perpendicular to the mouthpiece to exit the powder container; and wherein in a containment configuration the dry powder is sealed from the at least two air conduits and from the deflector or stem; wherein the powder container comprising a first vertical wall and a second vertical wall parallel and opposed; wherein in the dosing configuration the deflector or stem is disposed between the first vertical wall and the second vertical wall.

Assignees

Inventors

Classifications

  • pressure meter · CPC title

  • having means for promoting or enhancing the flow, actively or passively · CPC title

  • Rotating swirling helical flow, e.g. by tangential inflows · CPC title

  • with air flow regulating means · CPC title

  • Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9802012B2 cover?
A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as i…
Who is the assignee on this patent?
Mannkind Corp
What technology area does this patent fall under?
Primary CPC classification A61M15/0005. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).